|
|
|
| home > epc > autumn 2002 > the role of the eu national agencies in european regulatory affairs |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
Some readers may be surprised to learn that the DIA annual US meeting provides a very good opportunity to learn about what's happening in European regulatory affairs. This year's DIA meeting held in June in Chicago, was no exception. Speakers included key personnel from the European Commission, the European Medical Evaluation Association (EMEA), the Committee for Proprietary Medicinal Products (CPMP) and various European national agencies. I was privileged to be able to chair one of the sessions in the regulatory affairs track. The aim of the session was to discuss the role of the national agencies in European regulatory affairs today. The role of these national agencies has changed considerably over the last few years, as discussed below.
When I started working in European regulatory affairs in 1989 it was usual to submit separate national dossiers to each EU member state (MS). In most cases these dossiers would be basically similar but they would be tailored to meet the specific requirements of each country. However, it was possible to submit for different indications in different member states, for example, depending on medical practice in that particular country.
Then in 1995 came the introduction of the centralised and mutual recognition (MR) systems. One of the key points of both of these systems is that they require identical dossiers to be submitted to each MS and at the end of the process either a single EU licence is granted (centralised system) or identical licenses are granted in all member states (MR system). Therefore, it is no longer possible to have different indications in different countries and the summary of product characteristics must be identical throughout the EU.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
BIO-Europe Spring® 2012 — 6th International Partnering Conference
19-21 March 2012, Amsterdam RAI Convention Center, Amsterdam, The Netherlands
BIO-Europe Spring is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe, and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.
More info >> |
|
 |
News and Press Releases |
 |
Pantec Biosolutions to Present P.L.E.A.S.E.® Professional for Transdermal Drug Delivery at DDP in Las Vegas
Pantec Biosolutions AG, the developer and manufacturer of P.L.E.A.S.E.® Professional, a state of the art portable laser device that sets new standards for safety, precision and versatility, today announced that it will be giving a scientific company presentation during the “Drug Delivery Partnerships” conference from 25th -27th January 2012 in Las Vegas, USA.
More info >> |
|
|
